PLMR
Zacks hit Palomar with the makeover brush
Palomar Holdings just got an upgrade from Zacks Research, which moved the insurer from Hold to Strong Buy and set a $150 price target. In analyst-speak, that’s the equivalent of someone updating your LinkedIn headline from “open to work” to “hot prospect.”
The catch: the chorus isn’t perfectly in sync
This isn’t one of those clean, everyone-loves-it moments. MarketBeat notes that Wall Street Zen cut Palomar to Hold in early March, and Weiss Ratings also downgraded it in April. So while Zacks is getting more bullish, the analyst crowd is still sounding a little like a group chat that can’t agree on brunch.
Why investors should care
Zacks also laid out some EPS forecasts, including FY2026 EPS of $8.99, which gives bulls something concrete to point at instead of just vibes. The stock’s analyst consensus is still a Buy, with an average target of $161.75, so the market is clearly still debating whether Palomar is underappreciated or just having a very expensive identity crisis.
Insiders are still cashing out
Adding a little spice: the article says insiders sold 66,632 shares over the last 90 days, worth about $8.18 million, including CEO Mac Armstrong and President Jon Christianson. That doesn’t automatically mean trouble, but when executives are trimming while analysts are cheering, you may want to read the room a little harder.
Big picture: this is a bullish analyst note, but not a clean one. The upgrade can support sentiment, yet the mix of downgrades and insider selling means investors probably shouldn’t treat this like a victory lap just yet.